



รายการอ้างอิง

- (1) Lohsoonthorn V, Dhanamun B, Williams MA. Prevalence of hyperuricemia and its relationship with metabolic syndrome in Thai adults receiving annual health exams. Arch Med Res 2006; 37(7):883-889.
- (2) Harris CM, Lloyd DC, Lewis J. The prevalence and prophylaxis of gout in England. J Clin Epidemiol 1995; 48(9):1153-1158.
- (3) Klemp P, Stansfield SA, Castle B, Robertson MC. Gout is on the increase in New Zealand. Ann Rheum Dis 1997; 56(1):22-26.
- (4) Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. Am J Kidney Dis 2002; 40(1):37-42.
- (5) Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Saag KG. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology (Oxford) 2005; 44(8):1038-1042.
- (6) Prior IA, Rose BS. Uric acid, gout and public health in the South Pacific. N Z Med J 1966; 65(405):295-300.
- (7) Champion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 1987; 82(3):421-426.
- (8) Bayliss R, Clarke C, Whitehead TP, Whitfield AG. The management of hyperuricaemia. J R Coll Physicians Lond 1984; 18(2):144-146.

- (9) Gibson T, Grahame R. Gout and hyperlipidaemia. Adv Exp Med Biol 1974; 41:499-508.
- (10) Myers AR, Epstein FH, Dodge HJ, Mikkelsen WM. The relationship of serum uric acid to risk factors in coronary heart disease. Am J Med 1968; 45(4):520-528.
- (11) Yano K, Rhoads G, Kagan A. Epidemiology of serum uric acid among 8000 Japanese-American men in Hawaii. J Chronic Dis 1977; 30(3):171-184.
- (12) Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000; 283(18):2404-2410.
- (13) Fessel WJ. High uric acid as an indicator of cardiovascular disease. Independence from obesity. Am J Med 1980; 68(3):401-404.
- (14) Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006; 54(8):2688-2696.
- (15) Desager JP, Hulhoven R, Harvengt C. Uricosuric effect of fenofibrate in healthy volunteers. J Clin Pharmacol 1980; 20(10):560-564.
- (16) Ka T, Inokuchi T, Tsutsumi Z, Takahashi S, Moriwaki Y, Yamamoto T. Effects of a fenofibrate/losartan combination on the plasma concentration and urinary excretion of purine bases. Int J Clin Pharmacol Ther 2006; 44(1):22-26.
- (17) Yamamoto T, Moriwaki Y, Takahashi S, Tsutsumi Z, Hada T. Effect of fenofibrate on plasma concentration and urinary excretion of purine bases and oxypurinol. J Rheumatol 2001; 28(10):2294-2297.

- (18) Bastow MD, Durrington PN, Ishola M. Hypertriglyceridemia and hyperuricemia: effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial. Metabolism 1988; 37(3):217-220.
- (19) Elisaf M, Tsimichodimos V, Bairaktari E, Siamopoulos KC. Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia. J Cardiovasc Pharmacol 1999; 34(1):60-63.
- (20) Noguchi Y, Tatsuno I, Suyama K, Shibata T, Yoshida T, Otsuka Y et al. Effect of fenofibrate on uric acid metabolism in Japanese hyperlipidemic patients. J Atheroscler Thromb 2004; 11(6):335-340.
- (21) Feher MD, Hepburn AL, Hogarth MB, Ball SG, Kaye SA. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. Rheumatology (Oxford) 2003; 42(2):321-325.
- (22) Hepburn AL, Kaye SA, Feher MD. Fenofibrate: a new treatment for hyperuricaemia and gout? Ann Rheum Dis 2001; 60(10):984-986.
- (23) Lee YH, Lee CH, Lee J. Effect of fenofibrate in combination with urate lowering agents in patients with gout. Korean J Intern Med 2006; 21(2):89-93.
- (24) Takahashi S, Moriwaki Y, Yamamoto T, Tsutsumi Z, Ka T, Fukuchi M. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis 2003; 62(6):572-575.
- (25) Hepburn AL, Kaye SA, Feher MD. Long-term remission from gout associated with fenofibrate therapy. Clin Rheumatol 2003; 22(1):73-76.
- (26) Keating GM, Ormrod D. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia. Drugs 2002; 62(13):1909-1944.

- (27) Trevaks G, Lovell RR. Effect of atromid and its components on uric acid excretion and on gout. Ann Rheum Dis 1965; 24(6):572-575.
- (28) de la SG, Cadarso C. Fenofibrate decreases plasma fibrinogen, improves lipid profile, and reduces uricemia. Clin Pharmacol Ther 1999; 66(2):166-172.
- (29) Yamamoto T, Moriwaki Y, Takahashi S, Tsutsumi Z, Hada T. Effect of fenofibrate on plasma concentration and urinary excretion of purine bases and oxypurinol. J Rheumatol 2001; 28(10):2294-2297.
- (30) Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977; 20(3):895-900.
- (31) Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. New York: Academic Press, 1988.
- (32) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106(25):3143-3421.
- (33) Elisaf M. Effects of fibrates on serum metabolic parameters. Curr Med Res Opin 2002; 18(5):269-276.
- (34) Ganotakis E, Tsimihodimos V, Bairaktari E, Rizos E, Athyros V, Seferiades C et al. Effects of various fibrates on serum alkaline phosphatase activity. Atherosclerosis 2002; 165(1):187-188.
- (35) Bairaktari ET, Tzallas CS, Tsimihodimos VK, Liberopoulos EN, Miltiados GA, Elisaf MS. Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia. J Cardiovasc Risk 1999; 6(2):113-116.

- (36) Despres JP, Lemieux I, Salomon H, Delaval D. Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels: a 12-week randomized trial. J Intern Med 2002; 251(6):490-499.
- (37) Farnier M, Bonnefous F, Debbas N, Irvine A. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia. Arch Intern Med 1994; 154(4):441-449.
- (38) Steinmetz A, Schwartz T, Hehnke U, Kaffarnik H. Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia. J Cardiovasc Pharmacol 1996; 27(4):563-570.
- (39) Botorff MB. Statin safety and drug interactions: clinical implications. Am J Cardiol 2006; 97(8A):27C-31C.
- (40) Davidson MH. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf 2006; 5(1):145-156.
- (41) Pasternak RC, Smith SC, Jr., Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002; 40(3):567-572.
- (42) Broeders N, Knoop C, Antoine M, Tielemans C, Abramowicz D. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol Dial Transplant 2000; 15(12):1993-1999.
- (43) Wilson MW, Lay LT, Chow CK, Tai HH, Robertson LW, Glauert HP. Altered hepatic eicosanoid concentrations in rats treated with the peroxisome proliferators ciprofibrate and perfluorodecanoic acid. Arch Toxicol 1995; 69(7):491-497.

ภาคผนวก

แบบฟอร์มสำหรับบันทึกข้อมูลงานวิจัย

Study ID Treatment No.

Gender 1. male 2. female

Date of birth

Weight kg Height cm BMI kg/m²

Current alcohol status 1. yes 2. no

Diagnosis of gouty arthritis 1. definite
..... 2. probable (ACR classification criteria)

Duration of disease months

Tophus 1. yes 2. no

Co-morbidity 1. Diabetes mellitus 2. Hypertension
..... 3. Dyslipidemia 4. Chronic kidney disease
..... 5. Obesity 6. Heart disease
..... 7. Malignancy 8. Others, specify

Current medication used

Urate-lowering agents

..... 1. Allopurinol dose mg/day duration months

..... 2. Benzbromarone dose mg/day duration months

..... 3. Probenecid dose mg/day duration months

..... 4. Sulfipyrazone dose mg/day duration months

Other medications

..... 1. Colchicine dose mg/day duration months

..... 2. Aspirin dose mg/day duration months

..... 3. Diuretics, specify

dose mg/day duration months

..... 4. Anti-hypertensive drugs, specify

dose mg/day duration months

..... 5. Statin, specify

dose mg/day duration months

..... 6. Others, specify

Laboratory results

	before treatment	after treatment
CBC		
Hb (g/dl)		
Hct (%)		
WBC count (cells/ μ l)		
Neutrophils (%)		
Lymphocytes (%)		
Eosinophils (%)		
Platelet counts (cells/ μ l)		
Serum		
FPG (mg/dl)		
BUN (mg/dl)		
Creatinine (mg/dl)		
Uric acid (mg/dl)		
Total cholesterol (mg/dl)		
Triglyceride (mg/dl)		
HDL-C (mg/dl)		
LDL-C (mg/dl)		
Albumin (mg/dl)		
Globulin (mg/dl)		
SGOT (U/L)		
SGPT (U/L)		
AP (U/L)		
CK (U/L)		
24-hr urine		
Uric acid (mg/day)		
Creatinine (mg/day)		
Volume (ml)		
CCr (ml/min)		

Adverse drug reactions

GI symptoms 1. yes 2. no

Muscle pain 1. yes 2. no

Rash 1. yes 2. no

Fatigue 1. yes 2. no

Dizziness 1. yes 2. no

Others, specify

Compliance %

ประวัติผู้เขียนวิทยานิพนธ์



ชื่อ	นายแพทย์ อธิพงศ์ สุทธิประเสริฐ
ภูมิลำเนา	กรุงเทพมหานคร
การศึกษา	แพทยศาสตรบัณฑิต เกียรตินิยมอันดับหนึ่ง คณะแพทยศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย ปีการศึกษา 2542
พ.ศ. 2543 - 2544	แพทย์ใช้ทุน โรงพยาบาลมหาราชนครราชสีมา จังหวัดนครราชสีมา
พ.ศ. 2544 - 2546	แพทย์ใช้ทุน โรงพยาบาลวังน้ำเขียว อำเภอวังน้ำเขียว จังหวัดนครราชสีมา
พ.ศ. 2546 - 2549	แพทย์ประจำบ้าน ภาควิชาอายุรศาสตร์ โรงพยาบาลจุฬาลงกรณ์
พ.ศ. 2549 - ปัจจุบัน	แพทย์ประจำบ้านต่อยอด และ อาจารย์ประจำ สาขาวิชาโรคข้อและรูมาติสซั่ม ภาควิชาอายุรศาสตร์ โรงพยาบาลจุฬาลงกรณ์

